![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Chronic HCV Infection: How Does Maturation of the
HCV Infected Patient Population Impact Drug Development - Gary Davis MD
|
|
|
Gary L Davis, M.D.
Director, General and Transplant Hepatology
Baylor University Medical Center
Dallas, TX
Reported by Jules Levin
The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
Boston, MA June 23-24, 2010
![](../images/062610/062610-4/image002.gif)
![](../images/062610/062610-4/image004.gif)
![](../images/062610/062610-4/image006.gif)
![](../images/062610/062610-4/image008.gif)
![](../images/062610/062610-4/image010.gif)
![](../images/062610/062610-4/image012.gif)
![](../images/062610/062610-4/image014.gif)
![](../images/062610/062610-4/image016.gif)
![](../images/062610/062610-4/image018.gif)
![](../images/062610/062610-4/image020.gif)
![](../images/062610/062610-4/image022.gif)
![](../images/062610/062610-4/image024.gif)
![](../images/062610/062610-4/image026.gif)
![](../images/062610/062610-4/image028.gif)
![](../images/062610/062610-4/image030.gif)
![](../images/062610/062610-4/image032.gif)
![](../images/062610/062610-4/image034.gif)
![](../images/062610/062610-4/image036.gif)
![](../images/062610/062610-4/image038.gif)
![](../images/062610/062610-4/image040.gif)
![](../images/062610/062610-4/image042.gif)
![](../images/062610/062610-4/image044.gif)
![](../images/062610/062610-4/image046.gif)
![](../images/062610/062610-4/image048.gif)
![](../images/062610/062610-4/image050.gif)
![](../images/062610/062610-4/image052.gif)
![](../images/062610/062610-4/image054.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|